Showing papers on "Xanthone published in 1988"
TL;DR: In this paper, a chemical examination of the dry fruit hulls of Garcinia mangostana yielded two new xanthones, a bis-pyrano xanthone, BR.
46 citations
TL;DR: Two new xanthones, 1,5,8-trihydroxy-3-methoxy-2[3-methyl-2-butenyl] xanthone and 1,6-dihydroxyl-3methoxyl-2]-xanthone were isolated from the leaves of Garcinia mangostana and their structures elucidated by 1H NMR, IR and mass spectral studies.
31 citations
27 citations
TL;DR: Cinnamic, benzoic, and m-hydroxybenzoic acids and benzophenone (1) are efficient precursors to mangostin (3) as discussed by the authors.
Abstract: Cinnamic, benzoic, and m-hydroxybenzoic acids and benzophenone (1) are efficient precursors to mangostin (3).
26 citations
TL;DR: Two new xanthone glycosides have been isolated from the root of Gentiana lutea on the basis of spectroscopic evidence and have been determined as 7-hydroxy-3-methoxy-1- O -primeverosylxanthone and 1-hydroxyphenyl Xanthone.
20 citations
TL;DR: In this paper, three new xanthone glycosides, viz. 3,5,6,7,8-pentamethoxyxanthone-1- O -rhamnosyl (1 → 6) glucopyranoside, 3, 5, 8-trimethoxy Xanthone -1-O -glucopyranoide and a chromone glycoide, have been isolated from the roots of Chrozophora prostrata.
18 citations
17 citations
TL;DR: The xanthone (EFG) and isoquinolone (BC) segments of cervinomycins have been synthesised and naphtho-annulated to the pentacyclic CDEFG portion of the antibiotic.
Abstract: The xanthone (EFG) and isoquinolone (BC) segments of cervinomycins have been synthesised, xanthone (5b) has been naphthoannulated to the pentacyclic CDEFG portion of the antibiotic.
13 citations
12 citations
TL;DR: From the aerial parts of Ixanthus viscosus, 1,8-dihydroxy-2,3,6-trimethoxy xanthone and 1,3-8-trihydroxy- 2,6dimethoxy Xanthone, were isolated tog
8 citations
TL;DR: In this article, the identification of the flavonoid (V) and results on the isolation and study of glycosides were presented. But they did not give additional information on the identification and analysis of the V and only showed that the V was 3,8"-bisapigenin.
Abstract: From the epigeal part of Hypericum aucheri Jaub. et Spach we have previously isolated kaempferol, quercetin, myricetin, isoquercitrin, and flavonoid (V) [i] and also 1,3,6,7tetrahydroxyxanthone and its 2-C-glucosid (mangiferin) [2, 3]. On the basis of its UV, IR, PMR, and mass spectra, substance (V) was provisionally identified as 3,8"-bisapigenin [4]. In the present communication we give additional information on the identification of the flavonoid (V) and present results on the isolation and study of glycosides.
Journal Article•
TL;DR: Red cell enzyme activities were inhibited completely and inhibition of pyruvate kinase and diphosphoglycerate phosphatase was most striking, which could result in elevation of 2,3-DPG levels.
Patent•
21 Oct 1988
TL;DR: A compound expressed by the formula (R is >= 2C alkyl, cinnamoyl or alkoxy) is a compound that can be used as an antiulcer agent, antiinfectant, antimicrobial agent, and plant growth retardant as mentioned in this paper.
Abstract: NEW MATERIAL:A compound expressed by the formula (R is >=2C alkyl, cinnamoyl or alkoxy). EXAMPLE:Tri-N-myristoylchitotriose. USE:An antiulcer agent, antiinfectant, antimicrobial agent, antihyperlipemia and plant growth retardant. PREPARATION:Xanthone is heated with a mineral acid such as concentrated hydrochloric acid in order to partially hydrolyze the xanthone to afford chitotriose hydrochloride, which is then reacted with an acid hydrochloride in the presence of a dilute alkali and as necessary a solvent at 0-50 deg.C, preferably room temperature.
Patent•
10 Mar 1988
Patent•
18 Jan 1988
TL;DR: In this paper, a drug containing a specific xanthone derivative, having uriosuric action as well as diuretic action and low side effect against liver and useful as a remedy for hypertension, edema, hyperuricemia and gout.
Abstract: PURPOSE:To provide a drug containing a specific xanthone derivative, having uriosuric action as well as diuretic action and low side effect against liver and useful as a remedy for hypertension, edema, hyperuricemia and gout. CONSTITUTION:The objective drug contains, as an active component, a compound of formula (W, X, Y and Z are H, halogen or 1-4C alkyl; A is H or together with X or Y form a methylene chain; B is hydroxymethyl, 1-4C alkoxycarbonyl or carboxyl; when X, Y and Z are H, A is H and B are carboxyl or alkoxycarbonyl, then W is not H or 7-methyl) or its non-toxic salt when B is carboxyl, e.g. 4-chloro-8-fluoro-9-oxo-9H-xanthen-3-yloxyacetic acid. The rate of application of the compound is usually about several mg-500mg, preferably 10-100mg daily for adult.